Brief: Acurx Announces Positive Phase 2B Results Showing 100% Of Patients Who Had Clinical Cure With Ibezapolstat Also Had Sustained Clinical Cure
11/12/2023 12:22
Dec 11 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX ANNOUNCES POSITIVE PHASE 2B RESULTS SHOWING 100% OF
PATIENTS WHO HAD CLINICAL CURE WITH IBEZAPOLSTAT ALSO HAD
SUSTAINED CLINICAL CURE
* ACURX PHARMACEUTICALS: FURTHER ANALYSES WILL BE
FORTHCOMING Q1
2024, AS DATA BECOME AVAILABLE, REGARDING OTHER ENDPOINTS, FROM
PHASE 2B TRIAL
Source text for Eikon: ID:nPn5FgBWPa
Further company coverage: ACXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsAcurx Pharmaceuticals Q1 net loss narrows as expenses fall
Brief: Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Brief: Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend
Acurx Pharma Q3 net loss narrows to $2 mln